1. Home
  2. NMCO vs XNCR Comparison

NMCO vs XNCR Comparison

Compare NMCO & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMCO
  • XNCR
  • Stock Information
  • Founded
  • NMCO 2019
  • XNCR 1997
  • Country
  • NMCO United States
  • XNCR United States
  • Employees
  • NMCO N/A
  • XNCR N/A
  • Industry
  • NMCO Finance/Investors Services
  • XNCR Biotechnology: Pharmaceutical Preparations
  • Sector
  • NMCO Finance
  • XNCR Health Care
  • Exchange
  • NMCO Nasdaq
  • XNCR Nasdaq
  • Market Cap
  • NMCO 560.1M
  • XNCR 565.1M
  • IPO Year
  • NMCO N/A
  • XNCR 2013
  • Fundamental
  • Price
  • NMCO $10.19
  • XNCR $7.23
  • Analyst Decision
  • NMCO
  • XNCR Buy
  • Analyst Count
  • NMCO 0
  • XNCR 8
  • Target Price
  • NMCO N/A
  • XNCR $26.43
  • AVG Volume (30 Days)
  • NMCO 207.6K
  • XNCR 623.7K
  • Earning Date
  • NMCO 01-01-0001
  • XNCR 08-06-2025
  • Dividend Yield
  • NMCO 5.43%
  • XNCR N/A
  • EPS Growth
  • NMCO N/A
  • XNCR N/A
  • EPS
  • NMCO N/A
  • XNCR N/A
  • Revenue
  • NMCO N/A
  • XNCR $146,929,000.00
  • Revenue This Year
  • NMCO N/A
  • XNCR N/A
  • Revenue Next Year
  • NMCO N/A
  • XNCR $28.84
  • P/E Ratio
  • NMCO N/A
  • XNCR N/A
  • Revenue Growth
  • NMCO N/A
  • XNCR N/A
  • 52 Week Low
  • NMCO $8.52
  • XNCR $7.07
  • 52 Week High
  • NMCO $11.64
  • XNCR $27.24
  • Technical
  • Relative Strength Index (RSI)
  • NMCO 46.07
  • XNCR 29.99
  • Support Level
  • NMCO $10.14
  • XNCR $7.07
  • Resistance Level
  • NMCO $10.28
  • XNCR $8.21
  • Average True Range (ATR)
  • NMCO 0.10
  • XNCR 0.54
  • MACD
  • NMCO 0.02
  • XNCR -0.20
  • Stochastic Oscillator
  • NMCO 72.73
  • XNCR 5.35

About NMCO Nuveen Municipal Credit Opportunities Fund

Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.

About XNCR Xencor Inc.

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Share on Social Networks: